Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer. “This work should help doctors know which patients’ prostate cancers will and won’t respond to the androgen deprivation therapy enzalutamide, which can slow prostate cancer growth by disrupting androgen receptor signaling,” said Antonina Mitrofanova, associate professor of Biomedical and Health Informatics, associate dean for research at the Rutgers School of Health Professions, researcher at Rutgers Cancer Institute of New Jersey, and lead author of the study. “We hope this gets effective treatment to more patients in less time, and we hope follow-up research makes the benefit that many patients receive from enzalutamide work longer.” To read the full story.